Symptom.ly's platform, eAsthma Tracker, has been proven to significantly reduce child asthmatic hospital readmissions. It tracks symptoms, notifies physicians of progress, and can be expanded to include other chronic diseases such as cardiovascular, COPD, hypertension, and diabetes. The initial target market is the $3.6 billion market for asthmatic children, with potential expansion into the $17.5 billion cardiovascular market. The company's management team has strong industry relationships, and their sales and marketing strategy focuses on data-driven solutions and partnerships with insurance payers and Children's Hospitals. The business model includes licensing their platform-as-a-service and developing customer-specific modules, while also collecting valuable population health data. Symptom.ly's competitive advantages include clinical validation, exclusive licensing, and a pending patent.